Screener
Arcutis Biotherapeutics, Inc. ARQT Business Segments — Net loss
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Arcutis Biotherapeutics, Inc. in its filing.
Tagged under the XBRL concept us-gaap:NetIncomeLoss.
The source filing: Arcutis Biotherapeutics, Inc.’s 10-Q, filed August 5, 2026.
- Filed
- Aug 5, 2026, 4:21 PM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001787306-26-000051
| Line item | Three Months Ended June 30, 2026 | Three Months Ended June 30, 2025 | Six Months Ended June 30, 2026 | Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Total other income (expense) | (1,284) | (933) | (3,397) | (1,185) |
| Income (loss) before income taxes | 15,145 | (15,544) | 3,943 | (40,325) |
| Provision for income taxes | 136 | 342 | 229 | 621 |
| Net income (loss) | $15,009 | $(15,886) | $3,714 | $(40,946) |
| Other comprehensive income (loss): | ||||
| Unrealized gain (loss) on marketable securities | (96) | (95) | (447) | (232) |
| Foreign currency translation adjustment | (46) | 200 | (165) | 204 |
| Total other comprehensive income (loss) | (142) | 105 | (612) | (28) |
Item 1. Financial Statements (Unaudited)
FAQ
- What is Arcutis Biotherapeutics, Inc.'s business segments — net loss?
- Arcutis Biotherapeutics, Inc. (ARQT) reported business segments — net loss of $15.01M in Q2 2026.
- How has Arcutis Biotherapeutics, Inc.'s business segments — net loss changed year-over-year?
- Arcutis Biotherapeutics, Inc.'s business segments — net loss increased by 194.5% year-over-year, from -$15.89M to $15.01M.
- What is the long-term trend for Arcutis Biotherapeutics, Inc.'s business segments — net loss?
- Over 2 years (2022 to 2024), Arcutis Biotherapeutics, Inc.'s business segments — net loss has grown at a -32.9% compound annual growth rate (CAGR), from -$311.46M to -$140.04M.
- What does business segments — net loss mean?
- This metric represents the bottom-line financial result for the reportable segment after deducting all operating expenses, interest, and taxes from total revenues. A negative value indicates that the segment's costs and investments in growth or research exceed its generated revenue. It serves as a primary indicator of the segment's current path toward operational sustainability and financial viability.
Ask your AI about Arcutis Biotherapeutics, Inc.'s business segments — net loss.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude